Please assess the completion status of the following clinical trial:

Trial Title: Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. men and women 30-80 years of age inclusive~2. type 2 diabetes mellitus diagnosed by a physician within 3 years prior to patient enrollment~3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks prior to screening and randomization~4. HbA1C ≤ 8.5% on no oral hypoglycemic agents or HbA1C ≤ 7.5% on 1 agent or on half-maximal doses of 2 agents~5. body mass index ≥ 23 kg/m2~6. a negative pregnancy test and an agreement to use a reliable method of birth control for the duration of the trial in all females with childbearing potential~7. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG)~8. ability and willingness to self-inject insulin~9. provision of informed consent.~Exclusion Criteria:~1. current use of insulin therapy~2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance~3. renal dysfunction as evidenced by serum creatinine (Cr) ≥ 124 μmol/l~4. history of lactic acidosis or diabetic ketoacidosis~5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper limit of normal at the time of enrollment~6. history of inflammatory bowel disease, colonic ulcers, recent or significant bowel surgery, or predisposition to bowel obstruction~7. cardiovascular disease including any of:~   * systolic blood pressure \>180 mmHg or diastolic blood pressure \>105 mmHg~  * peripheral vascular disease~  * left bundle branch block or third degree AV block~  * tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate~  * stenotic valvular heart disease~  * cardiomyopathy~  * history of heart failure~  * history of aortic dissection~  * documented history of angina or coronary artery disease~  * history of stroke or transient ischemic attack~8. pulmonary disease with dependence on oxygen~9. history of any disease requiring intermittent or continuous systemic glucocorticoid treatment~10. history of any major illness with a life expectancy of \<3 years~11. history of injury or any other condition that significantly limits participant's ability to achieve moderate levels of physical activity~12. any history of excessive alcohol intake, acute or chronic~13. known hypersensitivity to metformin, acarbose, or insulin glargine.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (short) (Type: EXPERIMENTAL): None
- Group 2 (long) (Type: EXPERIMENTAL): None
- Standard care (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).